Advancing Therapeutic Options Around the World
Astellas Anemia Partnership
FibroGen and Astellas have been collaborating on hypoxia-inducible factor (HIF) anemia programs since 2004, first for Japan, and then for a broader territory covering Europe, the Middle East, the Commonwealth of Independent States, and South Africa. The strategic collaboration between the two companies brought the roxadustat programs to Phase 3 clinical development first among all hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor programs. Together with Astellas and AstraZeneca (our partner for the rest-of-world), we are well-positioned to bring new treatment options to patients suffering from anemia around the world.
AstraZeneca Anemia Partnership
In 2013, FibroGen and AstraZeneca entered into an anemia partnership for the U.S., and all other markets not licensed to Astellas, and for China. Our collaboration leverages FibroGen China’s strategy to bring the world-class innovation to China first, and AstraZeneca’s strong global footprint in the commercialization of pharmaceutical products.
Eluminex Biosynthetic Cornea Partnership
In July 2021, Eluminex exclusively licensed global rights from FibroGen to develop and commercialize an investigational biosynthetic cornea derived from recombinant human collagen Type III for patients with corneal blindness. The Eluminex biosynthetic cornea (EB-301) is a clinical stage corneal stromal substitute that will be developed for the China market initially. Additionally, Eluminex licensed all rights globally to develop other products based on the underlying recombinant human collagen Type III.
In June 2021, FibroGen exclusively licensed all product candidates in HiFiBiO Therapeutics’ Galectin-9 program, obtaining sole rights to develop and commercialize products worldwide. FibroGen also obtained an exclusive option to two other HiFiBiO programs, and subsequently exercised one of its exclusive options licensing all product candidates in HiFiBiO’s CCR8 program. This transformative partnership enables up to two INDs in 2023, expanding our development pipeline in FibroGen’s core research areas.